The QualityStocks Daily Friday, September 16th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(VNTH) $0.0016 +100.00%

FreeRealTime(AAOI) $3.7600 +50.40%

Schaeffer's(AVYA) $1.8800 +10.59%

The QualityStocks Daily Stock List

Bantec (BANT)

We reported earlier on Bantec (BANT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bantec Inc. (OTC: BANT) is a product and service firm that is focused on the research, design, development, testing, production, distribution and integration of military products which include advanced low altitude unmanned aerial vehicle systems and related technologies across the globe.

The enterprise, which was formerly known as Bantek Inc., provides its services in the United States and operates as part of the Aerospace products and parts manufacturing industry. It has its headquarters in Little Falls, New Jersey and was founded in 1972, on June 26th.

The firm has operations based in Vancouver, Washington as well as West Haven, Connecticut and pursues strategic partnerships and acquisitions with UAV companies. It offers a technological spectrum of drones, which have applications in theatres, agriculture, commercial enterprises, governments and in defense.

In addition to providing construction/environmental services and products and logistics services, the company uses its bantec.store website to sell drones, drone accessories and training services to the U.S. government, security companies, fire departments and law enforcement; to supply replacement and spare parts to commercial customers, U.S military prime contractors and federal government agencies and selling disinfecting equipment and products to building owners, manufacturers, universities and health facility owners. It also provides certificates of authorization for drones.

The firm, through its subsidiary, recently received purchase orders to supply the Fire and Emergency Management Department in Atlantic City with drone equipment. Drones are an effective tool that’ll help first responders do their work more efficiently. This contract is probably the first of many, which will help boost the firm’s sales as well as their growth.

Bantec (BANT), closed Friday's trading session at $0.0005, up 42.8571%, on 278,076,067 volume. The average volume for the last 3 months is 278.076M and the stock's 52-week low/high is $0.000293/$0.00465.

Anixa Biosciences (ANIX)

StockMarketWatch, Shiznit Stocks, Penny Stock General, MarketClub Analysis, The FrontPageStocks, MassiveStockProfits, MarketBeat, TradersPro, Trades Of The Day and StocksEarning reported earlier on Anixa Biosciences (ANIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Anixa Biosciences Inc. (NASDAQ: ANIX) (FRA: US3528H109) is a biotechnology firm that is focused on the development of vaccines and therapies for unmet needs in infectious diseases and oncological ailments.

The firm has its headquarters in San Jose, California and was incorporated in 1982, on November 5th. Prior to its name change in October 2018, the firm was known as Itus Corporation. It serves consumers in the U.S. and is party to a collaboration agreement with MolGenie GmbH which entails the discovery and development of anti-viral drug formulations against the coronavirus.

The company operates through the legacy patent licensing activities, cancer therapeutics and cancer diagnostics segments. The cancer therapeutics segment is engaged in the provision of CAR-T (chimeric antigen receptor T-cell) based immune-therapy drugs which modify a patient’s immune cells to fight cancer. On the other hand, the cancer diagnostics segment is involved in the development of non-invasive and inexpensive blood tests that can be used to detect solid tumors early, dubbed the CchekTM platform, which has been based on the immunity system’s response to a malignancy.

The enterprise’s programs include CAR-T tech that has been developed to treat ovarian cancer and anti-viral drug formulations to treat the coronavirus. Its vaccine programs comprise of a vaccine against ovarian cancer and another against triple negative breast cancer.

The firm’s compounds have been found to be more effective against the Delta variant, which is behind the fourth wave of the coronavirus pandemic. While more tests are needed to prove its complete efficacy, the compound may soon be used in the manufacture of drugs or a vaccine for this fatal coronavirus strain, which addresses a significantly unmet need and will be good for investments into the firm.

Anixa Biosciences (ANIX), closed Friday's trading session at $5.71, up 27.4554%, on 597,983 volume. The average volume for the last 3 months is 597,983 and the stock's 52-week low/high is $2.30/$5.71.

Applied Optoelectronics (AAOI)

StocksEarning, Zacks, MarketBeat, MarketClub Analysis, Schaeffer's, InvestorPlace, StreetInsider, The Street, Barchart, StockMarketWatch, Daily Trade Alert, The Online Investor, Kiplinger Today, Trades Of The Day, Investment House, Profit Confidential, BUYINS.NET, The Best Newsletters, Investment U, InvestmentHouse, Investopedia, Hit and Run Candle Sticks, Louis Navellier, TraderPower, Rick Saddler, Marketbeat.com, The Stock Dork, Investing Signal, Investing Futures, INO.com Market Report, QualityStocks, Short Term Wealth and Market Intelligence Center Alert reported earlier on Applied Optoelectronics (AAOI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied Optoelectronics Inc. (NASDAQ: AAOI) (FRA: A59) is focused on designing, manufacturing and selling different fiber-optic networking products.

The firm has its headquarters in Sugar Land, Texas and was incorporated in 1997, on February 28th by Chih Hsiang Lin. It serves consumers across the globe, with a focus on the United States, the People’s Republic of China and Taiwan.

The company operates in Taipei, Ningbo and Taiwan and China, via its wholly owned subsidiary known as Prime World International Holdings Limited. This subsidiary operates a branch in Taipei, Taiwan, which is mainly involved in the manufacture of transceivers. It also conducts research and development activities for its transceiver products. In addition to this, the company has a research and development facility in the state of Georgia. Its customers include Microsoft, Facebook, Amazon, Cisco Systems and Arris Group. The company generates the majority of its revenue from Taiwan and China.

The enterprise uses its Molecular Beam Epitaxy fabrication process to manufacture its products, which include transceivers, transmitters, turn-key equipment and optical devices like photodiodes, subassemblies and laser diodes, as well as distribution, node and headend equipment, which allow for faster connections. It sells its products through indirect and direct sales channels. The enterprise serves the telecom equipment manufacturer, fiber-to-the-home, Cable Television Broadband and internet data center markets.

The firm recently released its financial results for the third quarter of 2021, with its CEO noting that they had observed an improvement in Datacom. Currently, the firm is focused on growing its CATV business.

Applied Optoelectronics (AAOI), closed Friday's trading session at $3.76, up 50.4%, on 77,414,189 volume. The average volume for the last 3 months is 77.414M and the stock's 52-week low/high is $1.48/$8.86.

Nano Mobile Healthcare (VNTH)

QualityStocks, Actual Gains, Stockpalooza, Promotion Stock Secrets, Honest Abe, BUYINS.NET, OTCPicks, TheMicrocapNews, PennyStockRumors.net, OTCSHUB, BullRally, OTCReporter, OTCPennyPicks.com, OTCNewsAlerts.com, MadPennyStocks, Liquid Tycoon, JumpingPennyStocks.com, HotOTCPicks.com, HotPennyInvest.com, CityOdds, Penny Stock Pick Report, HotOTCChina.com, HotOTCBuzz.com, HotOTC, FOX Penny Stocks, DSR News, Joe Penny Stocks, PennyTrader Publisher, WePickPennyStocks, The Penny Stock Bull, Super Nova Stock Picks, Super Hot Penny Stocks, StockRich, StockMister, StockEgg, SmartPennyInvest.com, Penny Stock MoneyTrain, Pumps and Dumps, Penny PayDay, PennyStockVille, PennyStocks24, PennyStockPromo, PennyStockProfessor, PennyPickAlerts, Penny Stock Pulse, Winning Penny Stock Picks, Penny Stock Pick Alert, Penny Stock Hub and RisingPennyStocks reported earlier on Nano Mobile Healthcare (VNTH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nano Mobile Healthcare Inc. (OTC: VNTH) is a mobile health technology firm that is focused on the development of point-of-care and personalized screening, using applications based on chemical sensing techniques.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2010, on April 21st. Prior to its name change in September 2015, the firm was known as Vantage Healthcare Inc. The firm serves consumers in the United States.

The company has focused its initial efforts on screening for the presence of illnesses or the use of drugs. It is party to a strategic partnership agreement with a translational research firm known as Theranostics Laboratory. The company operates as a subsidiary of Nanobeak LLC.

The enterprise’s products are the convergence of bio-informatics, wireless technology and nano-electronics. They are based on patented technology invented by NASA. It develops small, hand-held screening devices which analyze and detect common components known as Volatile Organic Compound Signatures, from an individual’s breath and offer an early indication of chronic illnesses like heart failure. The enterprise has identified 2 markets the device can be used in, i.e. detecting the presence of cannabis in a driver’s breath and detecting lung cancer. Its secondary device testing indications include contagious illnesses like strep throat and various forms of cancer.

The company recently ventured into a new market with the development of its NFTsByGamers.com platform, which will develop a marketplace for the exchange and creation of NFTs in the gaming community. This move expands the company’s reach and will positively influence investments into the company, as well as boost the company’s overall growth.

Nano Mobile Healthcare (VNTH), closed Friday's trading session at $0.0016, up 100%, on 1,672,789,458 volume. The average volume for the last 3 months is 1.673B and the stock's 52-week low/high is $0.0004/$0.0109.

PaxMedica Inc. (PXMD)

We reported earlier on PaxMedica Inc. (PXMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical-stage biopharmaceutical firm that is focused on developing APT (anti-purinergic drug therapies) to treat disorders with intractable neurologic symptoms.

The firm has its headquarters in Tarrytown, New York and was incorporated in 2018. Prior to its name change in April 2020, the firm was known as Purinix Pharmaceuticals LLC. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company develops innovative treatments for unmet needs in neurodevelopmental disorders. It is focused on anti-purinergic therapies, which target the excess production of purines in cells. Purine overexpression can offset homeostasis and result in the overproduction of ATP (cellular adenosine triphosphate). ATP is the main energy molecule in all living cells.

The enterprise’s lead programs are focused on a pair of prevalent and challenging conditions; FXTAS (Fragile X-associated tremor/ataxia) and ASD (Autism spectrum disorder). Its product pipeline is comprised of an intravenous formulation of suramin dubbed PAX-101, developed for the treatment of a range of indications, including ASD, Human African Trypanosomiasis, long COVID-19 syndrome and myalgic encephalomyelitis/chronic fatigue syndrome. It also develops an intranasal formulation of suramin dubbed PAX-102, for the treatment of various neurologic indications.

The firm, which remains focused on advancing its clinical programs,recently launched its IPO and began trading on the NASDAQ. This move opens it up to new growth opportunities that will drive investments into the firm and bolster its overall growth.

PaxMedica Inc. (PXMD), closed Friday's trading session at $3.16, off by 18.5567%, on 336,283 volume. The average volume for the last 3 months is 336,283 and the stock's 52-week low/high is $2.8006/$10.48.

iBio Inc. (IBIO)

InvestorPlace, BUYINS.NET, StockMarketWatch, PennyStocks24, SmarTrend Newsletters, Kiplinger Today, QualityStocks, StreetInsider, TradersPro, CRWEWallStreet, PennyOmega, DrStockPick, CRWEPicks, CRWEFinance, BestOtc, Streetwise Reports, StockHotTips, HotStockProfits, PennyToBuck, TopPennyStockMovers, PennyStockSpy, Top Stock Picks, The Wealth Report, Money Morning, Daily Trade Alert, The Online Investor, 007 Stock Chat, MarketBeat, Stock Analyzer, CustomerService, StockOodles, SmallCapNetwork, AimHighProfits, Stock Beast, Stock Roach, ChartPoppers, Ascending Stocks, StockHideout, Jet-Life Penny Stocks, Shiznit Stocks, Jason Bond, InvestorTrendz, AwesomeStocks, BullFreak, BullRally, HotOTC, Greenbackers, FatCat Stocks, Fast Money Alerts, Capital Equity Report, Daily Stock Motion, CoolPennyStocks, Penny Stock General, FeedBlitz, PennyInvest, Whisper from Wall Street, WealthMakers, Wallstreetlivechat, Trades Of The Day, The Street, StockStreetWire, StockRich, Stock Spike, Stock Shock and Awe, SmallCapStockPlays, Schaeffer's, OTPicks, PennyStockVille, MadPennyStocks, Pennybuster, Penny Stocks VIP, WiseAlerts, Penny Pick Insider, Otcstockexchange, OtcShortReport, OTCPicks, MyBestStockAlerts, MicroCapINPLAY, MassiveStockProfits, Marketbeat.com and RockingPennyStocks reported earlier on iBio Inc. (IBIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iBio Inc. (NYSE American: IBIO) (FRA: 0JVN) is a biotechnology firm that is engaged in the provision of contract development and manufacturing services to collaborators and 3rd party consumers.

The firm has its headquarters in Bryan, Texas and was incorporated in 1993, on April 15th by Robert B. Kay. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company operates through the Bioprocessing and the Biopharmaceuticals segments. It is party to a license agreement with Planet Biotechnology Inc., entailing the development of therapeutics for infectious illnesses. It is also party to a collaboration agreement with The Texas A&M University System, for the development of Covid-19 vaccine candidates. The company is also party to a collaboration agreement with CC-Pharming Ltd, as well as a license agreement with the University of Natural Resources and Life Sciences, Vienna.

The enterprise’s product candidates include IBIO-100, a formulation developed to treat idiopathic pulmonary fibrosis and systemic scleroderma; and a formulation dubbed IBIO-400, which has been developed to treat classical swine fever. It also develops vaccine candidates which include IBIO-200 and IBIO-201, for the prevention of severe acute respiratory syndrome coronavirus 2.

The firm is focused on advancing its multi-variant coronavirus next-generation vaccine candidate, IBIO-202. The success and approval of this vaccine will meet the need for a vaccine which protects against existing and potentially new variants. This will not only benefit individuals around the globe but also drive investments into the firm.

iBio Inc. (IBIO), closed Friday's trading session at $0.46, up 49.8371%, on 11,378,137 volume. The average volume for the last 3 months is 11.378M and the stock's 52-week low/high is $0.22/$1.24.

Viking Therapeutics (VKTX)

MarketClub Analysis, MarketBeat, StockMarketWatch, Kiplinger Today, StreetInsider, Schaeffer's, InvestorPlace, Market Intelligence Center Alert, BUYINS.NET, QualityStocks, The Street, TraderPower, The Online Investor, Marketbeat.com, Wealth Insider Alert, Promotion Stock Secrets, Early Bird, DreamTeamNetwork, Investors Alley, PennyPro, Trades Of The Day, Trading Concepts and Money Morning reported earlier on Viking Therapeutics (VKTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Viking Therapeutics Inc. (NASDAQ: VKTX) (LON: 0VQA) (FRA: 1VT) is a clinical-stage biopharmaceutical firm that is focused on developing new therapies for endocrine and metabolic disorders.

The firm has its headquarters in San Diego, California and was incorporated in 2012, on September 24th by Michael A. Dinerman and Brian Lian. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s clinical programs are focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta (TRß) for adrenoleukodystrophy and lipid disorders like non-alcoholic steatohepatitis and hypercholesterolemia.

The enterprise’s product pipeline is comprised of an orally available tissue and receptor-subtype selective agonist of TRß known as VK0214, for X-linked adrenoleukodystrophy; and an orally available Phase 2b-ready drug candidate dubbed VK0612, for the management of type 2 diabetes. It also develops an orally available non-steroidal selective androgen receptor modulator dubbed VK5211, which is undergoing phase 2 trials for the treatment of patients recovering from non-elective hip fracture surgery. This is in addition to developing an orally available tissue and receptor-subtype selective agonist of TRß dubbed VK2809, which is undergoing phase 2b trials evaluating its effectiveness in treating non-alcoholic steatohepatitis.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on advancing its programs. The approval of its candidates for the treatment of a range of indications will not only benefit patients suffering from these illnesses but also bring in more investors into the firm, which will be good for its growth.

Viking Therapeutics (VKTX), closed Friday's trading session at $3.23, off by 2.7108%, on 528,403 volume. The average volume for the last 3 months is 528,403 and the stock's 52-week low/high is $2.02/$7.0453.

Comera Life Sciences (CMRA)

The Stock Dork reported earlier on Comera Life Sciences (CMRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Comera Life Sciences Holdings Inc. (NASDAQ: CMRA) is a preclinical stage life sciences firm that is focused on the development of an internal portfolio of therapies using its proprietary formulation platform.

The firm has its headquarters in Woburn, Massachusetts and was incorporated in 2022, on January 31st. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe.

The company is focused on the development of a new generation of bio-innovative biologic drugs to improve patient safety, access and convenience. Its approach is to put patients at the center of their treatment regimen, provide them with the freedom of self-injectable care and decrease institutional dependency. Its SQore platform has been designed to enable the conversion of IV (intravenous) biologics to SQ (subcutaneous) versions.

The enterprise is focused on the advancement of its primary product programs. These include its preclinical stage biobetter program dubbed CLS-001, for the treatment of Ulcerative Colitis disease and Crohn’s disease; and its preclinical stage biobetter program dubbed CLS-002, for a range of oncological indications. It also collaborates with biotechnology and pharmaceutical firms, applying its platform to their biologic medicines to deliver enhanced formulations which facilitate self-injectable care.

The company recently entered into a purchase agreement with Arena Business Solutions Global SPC II Ltd. These funds will allow the company to invest in its pipeline and will enable it to achieve its strategic objectives in the short-term. This will encourage more investments into the company and help create value for its shareholders.

Comera Life Sciences (CMRA), closed Friday's trading session at $2.48, off by 30.5322%, on 2,064,171 volume. The average volume for the last 3 months is 2.064M and the stock's 52-week low/high is $1.11/$11.44.

Swvl Holdings (SWVL)

QualityStocks, Wall Street.net, The Stock Dork and OTCPicks reported earlier on Swvl Holdings (SWVL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Swvl Holdings Corp (NASDAQ: SWVL) is a technology-driven mobility firm that is engaged in the provision of mass transit ridesharing services.

The firm has its headquarters in Dubai, the United Arab Emirates and was incorporated in 2017, on July 23rd. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The company is focused on providing safe, reliable, cost-effective and environmentally responsible mass transit solutions.

The enterprise provides a semi-private alternative to public transportation for individuals who can’t access or afford private options, as well as for those who’d prefer an alternative to taxi firms or other ridesharing firms. Its offerings include B2C Swvl Retail, which offers a network of minibuses and other vehicles to riders. These vehicles operate on semi-fixed or fixed routes within various cities. It also offers Swvl Travel, which enables riders to book rides on long-distance intercity routes on vehicles available on the company’s platform or via third-party services. In addition to this, the enterprise offers a transport as a service enterprise product known as Swvl Business, for schools, businesses and municipal transit agencies, among other clients. Currently, it operates in eighty-two cities in 7 countries.

The firm recently released its latest financial results, with its CEO noting that they remained focused on maintaining sustainable revenue growth and using its cloud platform to become more cost-efficient. This will not only increase adoption by consumers but also drive investments into the firm, which will positively influence overall growth.

Swvl Holdings (SWVL), closed Friday's trading session at $1.2, off by 2.439%, on 689,899 volume. The average volume for the last 3 months is 689,899 and the stock's 52-week low/high is $1.10/$11.40.

Southern Copper Corporation (SCCO)

SmarTrend Newsletters, MarketBeat, InvestorPlace, The Street, Louis Navellier, The Online Investor, Daily Wealth, Daily Trade Alert, The Wealth Report, TopStockAnalysts, Trades Of The Day, StreetAuthority Daily, Marketbeat.com, Zacks, Barchart, QualityStocks, Money Morning, TheStockAdvisor, Kiplinger Today, Schaeffer's, Market Intelligence Center Alert, MarketClub Analysis, Early Bird, Investopedia, Uncommon Wisdom, Top Pros' Top Picks, The Growth Stock Wire, Market Authority, The Stock Enthusiast, ChartAdvisor, TheStockAdvisors, INO.com Market Report, StreetInsider, InvestmentHouse, Investiv, Investing Futures, Greenbackers, Forbes, Investor Update, Dividend Opportunities, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, AllPennyStocks, DrStockPick, StockLockandLoad, Wealth Insider Alert, Wealth Daily, Vantage Wire, TradingMarkets, TradingAuthority Daily, The Tycoon Report, The Trading Report, The Motley Fool, MarketDNA, StockRockandRoll, InvestorGuide, StockHotTips, Profit Confidential, PennyToBuck, PennyOmega, Navellier Growth, Money and Markets, 24/7 Trader, InvestorsObserver Team, InvestorIntel and Streetwise Reports reported earlier on Southern Copper Corporation (SCCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earlier this week, the government of Chile led by President Gabriel Boric introduced a plan aimed at promoting investment into the country and spurring copper mining. Chile is the largest producer of copper in the world, making up 28% in global copper production. It is home to international copper giants, including Codelco, Antofagasta, Anglo American Glencore and BHP. The country is also the second-largest producer of lithium, occupying 22% of global production.

The investment package, dubbed Invest in Chile, brings together public resources, management efforts and regulatory changes. It also calls for the private sector to invest and participate in the nation’s decarbonization efforts.

In a news conference, the country’s Minister of Finance, Mario Marcel, stated that the plan was aimed at boosting investment by at least 5% during the coming year. The plan promotes private investment through tax benefits, which include extensions of reduced tax rates for small businesses, a half-a-billion tax credit fund for businesses with a high multiplying effect and depreciation mechanisms for the whole of next year. It also includes better access to financing and public investment to help the country’s weakened economy.

New mining projects for copper will also be exempt for five years from an ad-valorem tax that was put forward in a proposed mining royalty bill. This component would have imposed a tax on a mine’s production value. The proposed mining bill would also impose a rate on profits for copper prices between $2 to $5. It should be noted that the rate varies based on the price of copper.

The government also plans to reopen investment offices in North America and Europe, while also improving public-safety coordination, which players in the mining sector asked authorities to deal with after reports of an increase in violence that has affected operations in the northern region of Chile.

Furthermore, plans are underway to establish private-public working groups in sectors such as mining, transport, energy and construction. The plan also considers the creation of a regional committee of the aforementioned sectors, whose purpose will be to constantly monitor projects. This is in addition to reducing the number of halted projects and facilitating new initiatives in the mining, transportation, energy and construction sectors.

Last week, the country’s Central Bank revealed that it expected investments in 2022 to decrease by more than 3% and about 4.5% next year. In its latest Monetary Policy report, the bank stated that while the economy would grow in 2022, it would probably contract in 2023.

Copper extraction companies such as Southern Copper Corporation (NYSE: SCCO) operating in Chile are likely to give serious thought to the investment plan and see how they can benefit from any opportunities created in this scheme.

Southern Copper Corporation (SCCO), closed Friday's trading session at $46.68, off by 0.171086%, on 2,439,793 volume. The average volume for the last 3 months is 2.44M and the stock's 52-week low/high is $44.31/$79.315.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Daily Trade Alert, Trades Of The Day, StocksEarning, Kiplinger Today, The Online Investor, StreetInsider, Zacks, QualityStocks, StockMarketWatch, BUYINS.NET, INO Market Report, Cabot Wealth, Wealth Insider Alert, The Wealth Report, CNBC Breaking News, InvestorsUnderground, TradersPro, Investopedia, Early Bird, Daily Wealth, wyatt research newsletter, Energy and Capital, InvestorsObserver Team, CRWEWallStreet, InvestorIntel, MarketClub, Investors Alley, Jim Cramer, AllPennyStocks, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and Wealth Daily reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As the world collectively strives to cut carbon emissions, several countries around the globe have pledged to replace the conventional internal combustion engine (ICE) cars on their roads with zero-emission electric vehicles. Unlike ICE cars, EVs run on rechargeable lithium-ion battery packs and produce zero emissions at the tailpipe. But despite the lofty electrification plans of most countries, plenty of challenges stand in the way of mass electric vehicle adoption.

One of them, experts warn, is the energy crisis that has gripped the world for months. With energy prices rising on an almost daily basis, the cost of producing electric vehicles has gone up as well. As a result, carmakers have passed these extra costs onto the consumer, making electric vehicles even more expensive than they were before. Before the Russia-Ukraine war impacted global energy prices, electric vehicles were already too costly for most consumers.

Aside from range anxiety, exorbitant costs were the number-one reason keeping most drivers from going electric. But in recent months, as carmakers have contended with increased energy prices, EVs have become costlier, and automakers such as Tesla and General Motors have raised the prices of their electric offerings. With no end in sight for the global energy crisis, experts warn that electric vehicle adoption could be significantly impacted.

Increased electricity prices coupled with a chronic shortage of crucial parts, as well as the rise in the cost of raw materials threatens the future of EVs, experts believe. Coupled with a widespread drop in disposable income among consumers, these factors could massively hinder the adoption of battery electric vehicles (BEVs) over the next few years. Current electric vehicle owners are already being forced to dig deeper into their pockets to charge their cars.

In many European countries, including Germany, EV owners have seen their charging costs increase by 10% both at home and in charging stations as reduced gas inflows from Russia have threatened the energy supply. Establishments such as discount supermarkets that offered free EV charging to their customers have also begun introducing charges, a trend that automobile economist Stefan Bratzel believes is an immediate threat to the nascent electric vehicle industry.

The explosion in electricity prices could pose an acute danger to the transition to electric vehicles, he says, stating that if electric vehicle operational costs went up, the surge in EV adoption could collapse. He is among a group of advocates that is urging the German government to ensure electricity prices remain lower than gas prices to encourage EV adoption.

It is now up to electric vehicle makers such as NIO Inc. (NYSE: NIO) to find innovative ways around the production cost increases so that car buyers can still find the price of switching to EVs affordable.

NIO Inc. (NIO), closed Friday's trading session at $20.15, off by 6.3226%, on 65,778,725 volume. The average volume for the last 3 months is 65.779M and the stock's 52-week low/high is $11.67/$44.27.

Marathon Digital Holdings Inc. (MARA)

InvestorPlace, MarketClub Analysis, Schaeffer's, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, StocksEarning, Lebed.biz, BUYINS.NET, The Online Investor, Trades Of The Day, The Street, Daily Trade Alert, TraderPower, Marketbeat.com, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, FeedBlitz, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, InvestorsUnderground, Barchart, DreamTeamNetwork, RedChip, AllPennyStocks, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cryptocurrencies took the world by storm when they were first launched more than a decade ago. By the end of 2015, there were more than 10 million Bitcoin wallets worldwide, highlighting the popularity and explosive growth of the crypto market. Crypto promised to offer faster, more secure, and private transactions via the decentralized blockchain technology it is built on.

However, countries have taken to the disruptive technology differently, with some allowing their residents to hold and trade cryptocurrencies while others have passed extremely restrictive crypto laws. The following are the top countries around the world with strict cryptocurrency laws.

Russia recently made the news when the Bank of Russia filed a proposal to ban crypto mining and trading in the country. The bank argued that digital tokens such as Bitcoin posed a significant threat to Russia’s financial systems. At the moment, Russians are banned from using cryptos in their day-to-day payments.

China passed strict cryptocurrency regulations in 2021. The country’s government believes crypto presents too many problems, including promoting money laundering and harming the environment. China first began the crypto ban by asking financial institutions to refrain from engaging in any transactions involving cryptocurrency before later instructing all domestic crypto-mining operations to cease activities.

Egypt saw an Egyptian Islamic body called Dar al-Ifta pass a religious law against crypto giant Bitcoin in 2018, stating that its use is “haram.” Egypt’s banking laws also prevent citizens from making transactions by only allowing those with a Central bank license to trade Bitcoin.

Algeria has also outlawed all cryptocurrency transactions. Like Egypt, the country passed a law in 2018 that prohibited the possession, buying, selling and use of cryptocurrencies.

Bolivia was among the first countries in the world to pass restrictive cryptocurrency laws. The European nation banned the use of Bitcoin and a wide variety of other cryptocurrencies within its borders in 2014. Like China, Bolivia doesn’t believe cryptocurrencies have any merit, stating definitively that they “cannot be trusted as an investment.”

Bangladesh generally has strict regulations for its financial sector. Unfortunately, cryptocurrencies have been caught in the net, with the Asian country outlawing cryptocurrency trading and punishing individuals who are found buying, selling or using cryptos.

Turkey’s central bank banned the use of cryptos as a mode of payment in 2021, arguing that they are too big of a risk and can cause users “nonrecoverable” losses. The bank mentioned excessive volatility, lack of regulatory oversight and the potential for use in illegal activities as some of the risks involved with cryptos.

Those restrictive laws notwithstanding, the jurisdictions where cryptos are permitted are seeing plenty of companies such as Marathon Digital Holdings Inc. (NASDAQ: MARA) being established and thriving, to the benefit of the people they employ and the local economies in their areas of operation.

Marathon Digital Holdings Inc. (MARA), closed Friday's trading session at $10.92, off by 9.5278%, on 14,387,866 volume. The average volume for the last 3 months is 14.388M and the stock's 52-week low/high is $5.20/$83.45.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has weathered the geopolitical drama and international upheaval that fueled recession concerns amid spiking inflation. None of that stopped the company from having its best revenue quarter ever, spearheaded by horizontal and vertical growth. “The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021,” a recent article reads. “Meaningful progress in both its flagship business-to-business (‘B2B’) and new business-to-consumer (‘B2C’) divisions undergirded the jump in revenue. GMGI CEO Brian Goodman called the record quarter ‘even more impressive when considering the impact of global economic headwinds and an unfavorable exchange rate throughout the quarter.’… Record quarterly revenue was also spurred by Golden Matrix taking an 80% stake in RKings, the United Kingdom-based owner of a popular skill tournament platform operated in the U.K. and Ireland.” To view the full article, visit https://ibn.fm/RtEqM

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Friday's trading session at $3.98, up 6.9892%, on 170,684 volume. The average volume for the last 3 months is 170,684 and the stock's 52-week low/high is $3.2774/$10.72.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN) has, since its inception, sought to market the concept of “Lidar for Life,” introducing the use of lidar technology in mass-market consumer vehicles as well as the development of smart infrastructure in cities, spaces and industrial robotics. “As a pivotal part of its efforts in promoting lidar technology across different sectors, the company has invested in making lidar a truly scalable and accessible technology – cost efficient, reliable and easy to integrate into various systems,” a recent article reads. “Through its significant ADAS lidar series production award with Koito on the General Motors business, Cepton is leading the way in scaling up lidar for mass-market deployments. The scalability allows the company to expand its lidar use beyond automotive applications. This ranges from its efforts to resolve traffic congestion in major urban metropolises such as Austria’s mountainous landscapes to the collaboration with Lithuania-based system integrator Belam to improve road user and rail passenger safety using obstacle detection at crossings. Cepton’s scalability also reaches as far as incorporating lidar systems in security modalities. Bowler Pons, a specialist in technology-focused enhanced electronic security systems, is utilizing Cepton’s anonymous lidar systems for improved detection and categorization, ultimately enabling autonomous alerts while protecting privacy.” To view the full article, visit https://ibn.fm/d3Kwx

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Friday's trading session at $1.64, up 0.613497%, on 3,861,498 volume. The average volume for the last 3 months is 3.861M and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Cannabis is one of the fastest-growing industries in America. Just two decades after California first legalized medical and recreational cannabis, the industry has created hundreds of thousands of jobs and generates billions of dollars in sales revenue every year. Experts believe the cannabis space will become even more profitable as more states launch legal cannabis markets, predicting it will be worth a whopping $197.74 billion in 2028. Naturally, such mouth-watering profits have attracted numerous companies to the cannabis sector, with new organizations entering the space every year. Companies that want to stand out among the crowd and consistently attract customers will have to adopt strategies that allow them to gain a competitive edge. As the market gets increasingly crowded, innovative packaging could allow cannabis brands to remain competitive. Given that each market has its own peculiarities, companies such as Prime Harvest Inc. that are operating within those jurisdictions, have to come up with packaging that will promote their brands while adhering to the specific regulations in force within that legal market.

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.

Responsibility

Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.


Recent News

chart

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies has sought to position itself for the move away from fossil fuels through the launch of its revolutionary Smart Green(TM) Home system. “In a bid to transform every aspect of the living experience for the better, GeoSolar’s proprietary technology seeks to harness both the power of the sun and earth to fully electrify homes. From solar panels on roofs through to geothermal heat pumps, which take advantage of the warmth of the earth’s core, and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, the Smart Green(TM) Home system has been designed to dramatically increase the energy efficiency of a conventional household. Ultimately, the technology will seek to void the need for a home to depend on carbon-powered utilities or face increasingly exorbitant energy costs subject to volatile fossil fuel commodity prices,” a recent article reads. “GeoSolar Technologies has already successfully installed its revolutionary residential technology in multiple test homes across the state of Colorado, with tests revealing that households using the Smart Green(TM) Home system boasted some of the most impressive energy efficient ratings in the sector.” To view the full article, visit https://ibn.fm/TmNuV

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

  • EverGen reveals Q2 2022 financials and key growth milestones for expansion across Canada
  • Company acquired a 50% interest in Project Radius and a 67% interest in GrowTEC; agreed term sheet for CAD$31 million Senior Term Loan Facility with lenders Roynat and EDC
  • EverGen remains primed for a catalyst-rich second half of 2022; appears on track to boost RNG production to satisfy Canada’s swelling demand as consumers flock to the renewable natural gas space

"We have positioned EverGen as a leading RNG platform with a core operating portfolio and pipeline of projects in Canada set to deliver significant RNG volumes and accelerate the energy transition," were the words of Chase Edgelow, CEO of EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) as the company reported financial results as at and for the three- and six-month periods ended June 30, 2022 (https://ibn.fm/CboZ3). Second quarter updates and highlights include milestones such as expansion across Canada, where the company now boasts a presence in three of the country's four largest jurisdictions for RNG.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2, even for the day. The average volume for the last 3 months is 2,000 and the stock's 52-week low/high is $2.00/$4.21.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX) was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Doug Heldoorn, ACTX chairman and CEO, and Shannon Illingworth joined the broadcast, hosted by executive coach and speaker Sergio Tigera, to discuss the origins of Advanced Container Technologies and the ways it is working to revolutionize farming practices. “When I was speaking with Shannon – I’ve known him for 15 years – we were all in the same space. He was talking about growing these organic superfoods. It all flowed together, which was pretty cool,” Heldoorn said in the interview. “There was an opportunity to merge and get our brains together working toward a common goal of what’s missing in society right now. One [Grow Pod] will grow an acre of food with a third of the water it takes [for traditional farming] and less space, with no metals or toxins. Everybody right now is right on that bandwagon of doing things healthier and more responsible to the environment. We really think we’re on to something that’s going to be incredible.” To view the full press release, visit https://ibn.fm/6wshL

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.64, even for the day, on 527 volume. The average volume for the last 3 months is 527 and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

  • D-Wave has announced first ever demonstration of large-scale coherence in quantum annealers
  • New research findings open the door to simulations of exotic phases of matter (unusual states of matter, outside of liquid, solid or gas, that make up the universe) 
  • The company is further exploring the potential of annealing quantum computing for future products, services, and software applications

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, is focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials science, drug discovery, scheduling, fault detection, and financial modeling, and is the only provider building both annealing and gate-model quantum computers. Through its products, the company is unlocking commercial use cases in optimization today while building the technologies that enable new solutions for tomorrow. D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, has published a peer-reviewed milestone study of the first large-scale demonstration of coherent quantum annealing. For the first time, the research exhibits dynamics of a quantum phase transition in a large-scale programmable quantum annealing processor using up to 2000 qubits in a D-Wave processor. The announcement reads, “The paper---a collaboration between scientists from D-Wave, the University of Southern California, the Tokyo Institute of Technology, and Saitama Medical University---entitled ‘Coherent quantum annealing in a programmable 2000-qubit Ising chain,’ was published in the peer-reviewed journal Nature Physics today and is available here. The study shows that the fully programmable D-Wave quantum processor can be used as an accurate simulator of coherent quantum dynamics at large scales. This was demonstrated showing the patterns of ‘kinks’ separating correlated spins in almost perfect agreement with exact analytical solutions of the famous Schrodinger equation for an ideal quantum system, completely isolated from outside noise. The density and spacing of kinks depend on, among other things, the speed and ‘quantumness’ of the experiment. Measurements of single-qubit parameters were shown to accurately predict the behavior of systems from 8 to 2000 qubits, demonstrating high levels of control in quantum simulations at all scales.”

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $6.64, off by 20.1923%, on 229,067 volume. The average volume for the last 3 months is 229,067 and the stock's 52-week low/high is $5.40/$13.23.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an expiration date five years following the date of issuance. Aditxt anticipates the offering to close on or about Sept. 20, 2022, with H.C. Wainwright & Co. acting as exclusive placement agent for the offering. Based on the pricing, expected gross proceeds from the offering should reach an estimated $20 million, which Aditxt plans to use for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses as well as potential acquisitions or investments. To view the full press release, visit https://ibn.fm/2m5gr. Last week, the United States clocked one million organ transplants. This historic milestone was confirmed by the United Network for Organ Sharing at 12.50 p.m. ET. This private nonprofit organization is in charge of managing the sole organ transplantation and procurement network in the United States, under contract with the federal government. Details about the patient who received this millionth organ are unknown. Additionally, it is unclear what organ brought the number to one million. The first successful organ transplant was carried out decades ago, in 1954. It was conducted at Boston’s Brigham and Women’s Hospital by Dr. Joseph Murray. The procedure involved 23-year old identical twins, Richard and Ronald Herrick. During the surgery, Murray transplanted a kidney extracted from Ronald into Richard, who suffered from chronic kidney failure. With many companies such as Aditxt Inc. (NASDAQ: ADTX) seeking to commercialize various technologies that can reduce the rates of organ rejection in patients, the number of successful transplantations is sure to rise over the coming years and decades.

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Friday's trading session at $4.31, off by 58.5178%, on 8,241,204 volume. The average volume for the last 3 months is 8.241M and the stock's 52-week low/high is $4.30/$136.00.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world
  • Its latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products
  • Lexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular drugs market, projected to be valued at $107.8 billion by 2025

Since Lexaria Bioscience (NASDAQ: LEXX) began the development of its industry-leading DehydraTECH(TM) technology back in 2014, the company has remained steadfast in its goal to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes and dementia, among others.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.835, off by 3.2423%, on 81,147 volume. The average volume for the last 3 months is 81,147 and the stock's 52-week low/high is $1.85/$7.19.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Cannabis reform activists in Missouri received a reprieve after a state court dismissed a lawsuit against a ballot initiative that seeks to legalize cannabis in Missouri and facilitate the expungement of nonviolent cannabis-related charges. Soon after a cannabis reform initiative by Legal Missouri 2022 received state certification, prohibitionists filed a lawsuit asking that the initiative be dismissed. With the backing of Protect Our Kids PAC, Community Anti-Drugs Coalitions of America (CADCA) member Joy Sweeney filed a suit against the cannabis ballot initiative. Her suit claimed that the measure was not in line with single-subject rules for ballot measures as per Missouri’s constitution. Furthermore, the suit argued that there were irregularities in the ballot’s signature verifying process, suggesting that Secretary of State Jay Ashcroft may have intervened improperly. If the measure is approved during the November ballot, Missouri residents can look forward to having licensed companies, such as Flora Growth Corp. (NASDAQ: FLGC), that operate in other jurisdictions and serve clients there.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $1.02, off by 12.069%, on 340,069 volume. The average volume for the last 3 months is 340,069 and the stock's 52-week low/high is $0.586/$7.48.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

  • Cross-border shipping solutions developer Freight Technologies Inc. is a B2B marketplace builder focused on providing the commercial trucking industry with transparent and efficient automation to simplify necessary communications, coordination and paperwork
  • Freight Technologies, also known as Fr8Tech, upgraded its brand and ticker symbol earlier this year following its reverse merger with Hudson Capital Inc.
  • Amid the upgrade, the company is reporting new record quarterly revenue that grew by 60 percent over the previous quarter and 45 percent YOY
  • The company expects improving market conditions as the nation continues to rebound from COVID’s economic effects to drive long-term growth

At the height of the COVID pandemic two years ago, a large number of people found themselves out of work — many because of economic factors that ravaged day-to-day business cultures and others because they apparently decided it was a good time to choose more satisfying work (https://ibn.fm/gXIpx). The commercial trucking industry’s personnel shortages were a major factor in generating supply chain bottleneck frustrations that have further impacted the economy with retail product insecurity, but as vaccines have helped to drive a reopening of the labor market a newly diverse cadre of truckers, including minorities, women and family partners, has taken to the roads (https://ibn.fm/JAs21). The new blood in the trucking industry, as well as the ongoing challenges created by worker shortages, underline the need for using technology to simplify processes and eliminate inefficiencies in the movement along the supply chain. Over-the-road shipping technology innovator Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has developed a AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles.

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.88, off by 12.8713%, on 118,801 volume. The average volume for the last 3 months is 118,801 and the stock's 52-week low/high is $0.88/$8.734.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of only 6.8%, and the average length of survival for patients is estimated to be eight months,” explains a recent article. “Against the backdrop of statistics that show the aggressiveness of GBM, CNS is leading the charge to find a potential treatment option for the disease. ‘In the results of the first Berubicin clinical trial, 44% of the patients showed a clinical response, with one Durable Complete Response (a demonstrated lack of detectable cancer cells,’ CNS’s website reads. ‘Berubicin has shown evidence of improved survival in a patient population that currently has a dismal median survival rate of only 14.6 months from its diagnosis.’ Currently, the company is focusing on an ongoing, potentially pivotal global study that commenced in March last year.” To view the full article, visit https://ibn.fm/qqChE

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $0.238, off by 3.252%, on 107,191 volume. The average volume for the last 3 months is 107,191 and the stock's 52-week low/high is $0.20/$1.63.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.